Pharmacogenomics FAQ | NHGRI

Posted on by

Much research is underway to understand how genomic information can be used to develop more personalized and cost-effective strategies for using drugs to improve human health.

In 2007, the FDA revised the label on the common blood-thinning drug warfarin (Coumadin) to explain that a person's genetic makeup might influence response to the drug. Some doctors have since begun using genetic information to adjust warfarin dosage. Still, more research is needed to conclusively determine whether warfarin dosing that includes genetic information is better than the current trial-and-error approach.

The FDA also is considering genetic testing for another blood-thinner, clopidogrel bisulfate (Plavix), used to prevent dangerous blood clots. Researchers have found that Plavix may not work well in people with a certain genetic variant.

Cancer is another very active area of pharmacogenomic research. Studies have found that the chemotherapy drugs, gefitinib (Iressa) and erlotinib (Tarceva), work much better in lung cancer patients whose tumors have a certain genetic change. On the other hand, research has shown that the chemotherapy drugs cetuximab (Erbitux) and panitumumab (Vecitibix) do not work very well in the 40 percent of colon cancer patients whose tumors have a particular genetic change.

Pharmacogenomics may also help to quickly identify the best drugs to treat people with certain mental health disorders. For example, while some patients with depression respond to the first drug they are given, many do not, and doctors have to try another drug. Because each drug takes weeks to take its full effect, patients' depression may grow worse during the time spent searching for a drug that helps.

Recently, researchers identified genetic variations that influence the response of depressed people to citalopram (Celexa), which belongs to a widely used class of antidepressant drugs called selective serotonin re-uptake inhibitors (SSRIs). Clinical trials are now underway to learn whether genetic tests that predict SSRI response can improve patients' outcomes.

See original here:
Pharmacogenomics FAQ | NHGRI

Irinotecan – Wikipedia

Posted on by

IrinotecanClinical dataTrade namesCamptosar (US), Campto (EU), Onivyde (liposomal)AHFS/Drugs.comMonographMedlinePlusa608043Pregnancycategory

O=C7OCC=6C(=O)N2C(c1nc5c(c(c1C2)CC)cc(OC(=O)N4CCC(N3CCCCC3)CC4)cc5)=C/C=6[C@@]7(O)CC

Irinotecan, sold under the brand name Camptosar among others, is a medication used to treat colon cancer and small cell lung cancer.[1] For colon cancer it is used either alone or with fluorouracil.[1] For small cell lung cancer it is used with cisplatin.[1] It is given by slow injection into a vein.[1]

Common side effects include diarrhea, vomiting, bone marrow suppression, hair loss, shortness of breath, and fever.[1] Other severe side effects include blood clots, colon inflammation, and allergic reactions.[1] Those with two copies of the UGT1A1*28 gene variant are at higher risk for side effects.[1] Use during pregnancy can result in harm to the baby.[1] Irinotecan is in topoisomerase inhibitor family of medication.[2] It works by blocking topoisomerase 1 which results in DNA damage and cell death.[1]

Irinotecan was approved for medical use in the United States in 1996.[1] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] In the United Kingdom it is available as a generic medication and costs the NHS about 114.00 pounds per 100mg.[2] It is made from the natural compound camptothecin.[1]

Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan. The regimen XELIRI consists of capecitabine and irinotecan.[4][5]

The most significant adverse effects of irinotecan are severe diarrhea and extreme suppression of the immune system.[6]

Irinotecan-associated diarrhea is severe and clinically significant, sometimes leading to severe dehydration requiring hospitalization or intensive care unit admission. This side-effect is managed with the aggressive use of antidiarrheals such as loperamide or co-phenotrope with the first loose bowel movement.

The immune system is adversely impacted by irinotecan. This is reflected in dramatically lowered white blood cell counts in the blood, in particular the neutrophils. The patient may experience a period of neutropenia (a clinically significant decrease of neutrophils in the blood) while the bone marrow increases white cell production to compensate.

Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.[6]

The molecular action of irinotecan occurs by trapping a subset of topoisomerase-1-DNA cleavage complexes, those with a guanine +1 in the DNA sequence.[7] One irinotecan molecule stacks against the base pairs flanking the topoisomerase-induced cleavage site and poisons (inactivates) the topoisomerase 1 enzyme.[7]

Click on genes, proteins and metabolites below to link to respective articles. [ 1]

Irinotecan is converted by an enzyme into its active metabolite SN-38, which is in turn inactivated by the enzyme UGT1A1 by glucuronidation.

People with variants of the UGT1A1 called TA7, also known as the "*28 variant", express fewer UGT1A1 enzymes in their liver and often have Gilbert's syndrome. During chemotherapy, they effectively receive a larger than expected dose because their bodies are not able to clear irinotecan as fast as others. In studies this corresponds to higher incidences of severe neutropenia and diarrhea.[8]

In 2004, a clinical study was performed that both validated prospectively the association of the *28 variant with greater toxicity and the ability of genetic testing in predicting that toxicity before chemotherapy administration.[8]

In 2005, the FDA made changes to the labeling of irinotecan to add pharmacogenomics recommendations, such that irinotecan recipients with a homozygous (both of the two gene copies) polymorphism in UGT1A1 gene, to be specific, the *28 variant, should be considered for reduced drug doses.[9] Irinotecan is one of the first widely used chemotherapy agents that is dosed according to the recipient's genotype.[10]

Irinotecan received accelerated approval from the U.S. Food and Drug Administration (FDA) in 1996 and full approval in 1998.[11][12]

During development, it was known as CPT-11.

A liposome encapsulated version of irinotecan sold as Onivyde, was approved by FDA in October 2015 to treat metastatic pancreatic cancer.[13] It gained EU approval in October 2016.[14]

Read more:
Irinotecan - Wikipedia

Omics – Wikipedia

Posted on by

The English-language neologism omics informally refers to a field of study in biology ending in -omics, such as genomics, proteomics or metabolomics. The related suffix -ome is used to address the objects of study of such fields, such as the genome, proteome or metabolome respectively. Omics aims at the collective characterization and quantification of pools of biological molecules that translate into the structure, function, and dynamics of an organism or organisms.

Functional genomics aims at identifying the functions of as many genes as possible of a given organism. It combines different -omics techniques such as transcriptomics and proteomics with saturated mutant collections.[1]

The suffix -ome as used in molecular biology refers to a totality of some sort; it is an example of a "neo-suffix" formed by abstraction from various Greek terms in -, a sequence that does not form an identifiable suffix in Greek.

The Oxford English Dictionary (OED) distinguishes three different fields of application for the -ome suffix:

The -ome suffix originated as a variant of -oma, and became productive in the last quarter of the 19th century. It originally appeared in terms like sclerome[2] or rhizome.[3] All of these terms derive from Greek words in -,[4] a sequence that is not a single suffix, but analyzable as --, the -- belonging to the word stem (usually a verb) and the - being a genuine Greek suffix forming abstract nouns.

The OED suggests that its third definition originated as a back-formation from mitome,[5] Early attestations include biome (1916)[6] and genome (first coined as German Genom in 1920[7]).[8]

The association with chromosome in molecular biology is by false etymology. The word chromosome derives from the Greek stems ()- "colour" and ()- "body".[8] While "body" genuinely contains the - suffix, the preceding -- is not a stem-forming suffix but part of the word's root. Because genome refers to the complete genetic makeup of an organism, a neo-suffix -ome suggested itself as referring to "wholeness" or "completion".[9]

Bioinformaticians and molecular biologists figured amongst the first scientists to apply the "-ome" suffix widely. Early advocates included bioinformaticians in Cambridge, UK, where there were many early bioinformatics labs such as the MRC centre, Sanger centre, and EBI (European Bioinformatics Institute). For example, the MRC centre carried out the first genome and proteome projects.

Lipidome is the entire complement of cellular lipids, including the modifications made to a particular set of lipids, produced by an organism or system.

Proteome is the entire complement of proteins, including the modifications made to a particular set of proteins, produced by an organism or system.

Glycomics is the comprehensive study of the glycome i.e. sugars and carbohydrates.

Foodomics was defined in 2009 as "a discipline that studies the Food and Nutrition domains through the application and integration of advanced -omics technologies to improve consumer's well-being, health, and knowledge"

Transcriptome is the set of all RNA molecules, including mRNA, rRNA, tRNA, and other non-coding RNA, produced in one or a population of cells.

Inspired by foundational questions in evolutionary biology, a Harvard team around Jean-Baptiste Michel and Erez Lieberman Aiden created the American neologism culturomics for the application of big data collection and analysis to cultural studies.

The word comic does not use the "omics" suffix; it derives from Greek ()- (merriment) + -()- (an adjectival suffix), rather than presenting a truncation of ()-.

Similarly, the word economy is assembled from Greek ()- (household) + ()- (law or custom), and economic(s) from ()- + ()- + -()-. The suffix -omics is sometimes used to create names for schools of economics, such as Reaganomics.

Many omes beyond the original genome have become useful and have been widely adopted by research scientists. Proteomics has become well-established as a term for studying proteins at a large scale. "Omes" can provide an easy shorthand to encapsulate a field; for example, an interactomics study is clearly recognisable as relating to large-scale analyses of gene-gene, protein-protein, or protein-ligand interactions. Researchers are rapidly taking up omes and omics, as shown by the explosion of the use of these terms in PubMed since the mid '90s.[15]

Read this article:
Omics - Wikipedia

Pharmacogenomics – 1st Edition – Elsevier

Posted on by

Dedication

List of Contributors

Preface

Chapter 1. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications

Objectives

Introduction

Cytochrome P-450 Enzymes

Non-CYP-450 Drug Metabolizing Enzymes

Polymorphisms in Drug Transporter Genes

Drug Target Genes

Conclusion

Questions for Discussion

References

Chapter 2. Translating Pharmacogenomic Research to Therapeutic Potentials

Objectives

Introduction

Implementation of Biomarkers in Clinical Practice

Incorporating Pharmacogenomics intoDrugDevelopment

Conclusion

Questions for Discussion

References

Chapter 3. Governmental and Academic Effortsto Advance the Field ofPharmacogenomics

Objectives

Introduction

The Role of the National Institutes of Health

The Role of the Food and Drug Administration and OtherInternational Government Agencies

Activities of Non-U.S. Agencies

Conclusion

Questions for Discussion

References

Chapter 4. Pharmacogenomics in Cancer Therapeutics

Objectives

Introduction

Role of Oncology Biomarkers

Concepts in Targeted Cancer Therapy

Oncology in the Postgenomic Era

Challenges in Drug Development and Cancer Trials

Seeking Pharmacogenomic Value

Questions for Discussion

References

Chapter 4A. A Look to the Future: CancerEpigenetics

Learning Objectives

Introduction

Histone Modification

DNA Methylation

Noncoding RNA (ncRNA)

Conclusion

Questions for Discussion

References

Chapter 5. Pharmacogenetics in Cardiovascular Diseases

Objectives

Introduction

Pharmacogenomics of Antiplatelet Agents

Warfarin Pharmacogenomics

Other Genetic Contributions to Warfarin Dose Variability and Response

Trials and Tribulations of Pharmacogenomics of Agents Used to Treat Dyslipidemia

Pharmacogenomic Potential in Heart Failure

Genetic Influences of Drug-Induced Arrhythmia

Conclusion

Discussion Points

Discussion Questions

References

Chapter 5A. A Look to the Future: Cardiovascular Pharmacoepigenetics

Learning objectives

Introduction

Opportunities

Challenges

Conclusion

Questions for Discussion

References

Chapter 6. Pharmacogenomics in Psychiatric Disorders

Objectives

Introduction

Polymorphisms in Proteins that Affect Drug Concentrations

Polymorphisms in Proteins that Mediate Drug Response

Application of Pharmacogenomics in Psychiatry

Conclusion

Questions for Discussion

References

Chapter 6A. A Look to the Future: Epigenetics in Psychiatric Disorders and Treatment

Objectives

Nature and Nurture Both Contribute to the Etiologies of Psychiatric Disorders

Epigenetic Processes Are Likely to Contribute to the Biochemical Basis of Nurture

Epigenetic Dysfunction Has Been Linked to Psychiatric and Neurological Disorders

Epigenetic Processes May Be Critical to Treatment Response in Psychiatric Disorders

Epigenetic Variation of Genes Regulating Pharmacokinetic Processes Is Likely to Influence Treatment Response

Epigenetic Modifications of Drug Transporters

Epigenetics and Adverse Drug Reactions

Limitations of Epigenetic Biomarkers in Psychiatry

Conclusion

Questions for Discussion

References

Chapter 7. The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management

Objectives

Introduction

Diabetes Overview

Type 2 Diabetes Pharmacogenomics

Challenges and Opportunities of Pharmacogenomics in Diabetes

Pharmacogenomics and HIV

Pharmacogenomics and Pain Control

More here:
Pharmacogenomics - 1st Edition - Elsevier

Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players – PRNewswire

Posted on by

DUBLIN, Feb. 21, 2020 /PRNewswire/ -- The "Global Precision Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Precision Medicine market is expected to reach $144.4 billion by 2026, growing at a CAGR of 14.5% from 2018 to 2026.

Some of the factors such as increasing the acceptance rate of gene therapies in developed economies and growing advancements in cancer biology are fuelling market growth. However, high cost of the development and increasing price of genetic testing, is restraining the market growth.

Based on the technology, companion diagnostics segment has witnessed significant growth. Companion diagnostics help healthcare experts to assess the advantages and side-effects or risk of therapeutic products on a patient.

The key vendors mentioned are Teva Pharmaceutical Industries, Tepnel Pharma Services, Quest Diagnostics Incorporated, Qiagen, Pfizer, Novartis, Nanostring Technologies, Medtronic, Laboratory Corporation of America Holdings, Intomics, Hoffmann-La Roche, Ferrer inCode, Eagle Genomics, and Biocrates Life Sciences.

Key Questions Answered in the Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics3.1 Drivers3.2 Restraints

4 Market Environment

5 Global Precision Medicine Market, By Product5.1 Introduction5.2 Services5.3 Instruments5.4 Consumables

6 Global Precision Medicine Market, By Technology6.1 Introduction6.2 Targeted Therapeutics6.3 Molecular Diagnostics6.4 Gene Sequencing6.5 Drug Discovery6.6 Companion Diagnostics6.7 Bioinformatics6.8 Big Data Analytics6.9 Pharmacogenomics (PGX)6.10 Other Technologies

7 Global Precision Medicine Market, By Therapeutics7.1 Introduction7.2 Genetic Tests7.3 Direct to Consumer Tests7.4 Immunology7.5 Gastroenterology7.6 Neurology/Physiatry7.7 Infectious Diseases7.8 Central Nervous System (CNS)7.9 Cardiovascular Disease (CVD)7.10 Cancer/Oncology7.11 Skin Diseases7.12 Respiratory Diseases7.13 Renal Disease7.14 Pulmonary Disease7.15 Ophthalmology7.16 Metabolic Disease7.17 Hematology

8 Global Precision Medicine Market, By End-user8.1 Introduction8.2 Pharmaceutical Companies8.3 Medical Devices8.4 Hospitals8.5 Home Care8.6 Diagnostic Companies8.7 Biotechnology Companies8.8 Healthcare-IT/Big Data firms8.9 Clinical Laboratories

9 Global Precision Medicine Market, By Geography9.1 Introduction9.2 North America9.3 Europe9.4 Asia-Pacific9.5 South America9.6 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape11.1 Teva Pharmaceutical Industries Ltd.11.2 Tepnel Pharma Services11.3 Quest Diagnostics Incorporated11.4 Qiagen N.V.11.5 Pfizer Inc.11.6 Novartis AG11.7 Nanostring Technologies11.8 Medtronic11.9 Laboratory Corporation of America Holdings11.10 Intomics11.11 Hoffmann-La Roche11.12 Ferrer inCode11.13 Eagle Genomics Ltd.11.14 Biocrates Life Sciences AG

For more information about this report visit https://www.researchandmarkets.com/r/i41sk8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the rest here:
Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players - PRNewswire

Updating the landscape of direct-to-consumer pharmacogenomic testing – Dove Medical Press

Posted on by

Back to Browse Journals Pharmacogenomics and Personalized Medicine Volume 10

Kelly K Filipski,John D Murphy,Kathy J Helzlsouer

Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA

Abstract: Pharmacogenomics has identified important druggene interactions that affect the safety and efficacy of medications. Direct-to-consumer genetic testing, when first introduced, included some pharmacogenomic-related genes. The current landscape of pharmacogenomic direct-to-consumer testing is reviewed. Prior published reviews of the literature were updated through February 2017 and a scan of the current availability of direct-to-consumer genomic testing by companies was conducted. Results of the review demonstrate a shift toward physician-approved ordering.

Keywords: pharmacogenomics, direct-to-consumer testing

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original post:
Updating the landscape of direct-to-consumer pharmacogenomic testing - Dove Medical Press

Global Molecular Diagnostics Market is Likely to Surpass US$ 22.5 Billion by the End of Year 2025 – ResearchAndMarkets.com – Yahoo Finance

Posted on by

The "Molecular Diagnostics Market Share & Global Forecast, By Application, Technology, End User, Regions, Companies" report has been added to ResearchAndMarkets.com's offering.

Increasing prevalence of Infectious diseases such as Influenza, HPV, Hepatitis, HIV and Tuberculosis despite rise in sanitation practices globally. In the past, antimicrobials medicines were used to fight powerful infectious disease but slowly in today's time antimicrobial agent is not able to give the desired results because the problem of drug resistant occurs in many people across the world.

Nowadays, a new diagnostic procedure is being followed to fight infectious disease like molecular diagnostic test is very effective which is quite fast and precise. The number of cancer patients is increasing very fast, so it is believed that in the coming time the molecular diagnostic test market will be growing at rapid pace. Global Molecular Diagnostics Market is likely to surpass US$ 22.5 Billion by the end of year 2025.

There are various reasons that will propel the market growth in forecast year; rising incidence rate of infectious disease, increasing incidence rate of cancer of all type, increasing people awareness regarding molecular diagnostic, rapid technological growth, widely acceptance of personalized medicine, rising healthcare infrastructure, increasing healthcare per capita expenditure across the developed and developing nation, accuracy of diagnosis, growing population of cardiovascular and neurological disorder etc. In addition, increasing prevalence of genetic disorder will further boost the market in forecast period of time.

The report titled Molecular Diagnostics Market Share & Forecast, By Application (Infectious Diseases, Blood Screening, Oncology, Genetic Testing, HLA (Tissue Typing), Microbiology, Cardiovascular Diseases, Neurological Diseases, Pharmacogenomics and Others), By Technology (PCR, Transcription-Mediated Amplification (TMA), Hybridiazation (In-situ Hybridiazation & FISH), DNA Sequencing & NGS, Microarray and Others), By End User (Hospitals & Academic Laboratories, Clinics and Commercial Laboratories, Others), By Regions [United States, Europe (Expect Russia), India, China, Japan, Brazil, South Korea, Mexico, Russia and ROW], Companies (Roche, Abbott, Myriad Genetics, Qiagen, BioMrieux and Others) provides a complete analysis of Molecular Diagnostics Market.

Story continues

Market Insight by Application

The report provides comprehensive analysis of molecular diagnostic test market by application into ten parts: Infectious Diseases, Genetic Testing, Blood Screening, Oncology, HLA (Tissue Typing), Microbiology, Neurological Diseases, Pharmacogenomics, Cardiovascular Diseases, and Others. This report also provides key opportunities market and specific factors are given by each application market.

Market Insight by Technology

Here the market is fragmented into six parts; PCR, Transcription-Mediated Amplification (TMA), Hybridiazation (In-situ Hybridiazation & FISH), DNA Sequencing & NGS, Microarray and Others. Besides, many factors are analyzed that influence the growth, challenges and opportunities of market in technological context.

Market Insight by End User

The report provides complete insight of market by End User segments: Hospitals & Academic Laboratories, Clinics & Commercial Laboratories and Others. According to the publisher, Hospitals & Academic Laboratories will hold the largest market in global molecular diagnostic test market in forecast period of time.

Market Insight by Regions

This report covers the complete regional profile by 10 geographical market; United States, Europe, India, China, Japan, Brazil, South Korea, Mexico, Russia and Rest of World (ROW).

Key Topics Covered:

1. Executive Summary

2. Global Molecular Diagnostic Market

3. Market Share - Global Molecular Diagnostics

3.1 By Application

3.2 By Technology

3.3 By Countries

3.4 By Companies

4. Application - Molecular Diagnostics Market

4.1 Infectious Diseases

4.1.1 Hospital Acquired Infections (HAI)

4.1.2 HIV / HCV Testing

4.1.3 STD Testing

4.1.4 HPV Testing

4.2 Blood Screening

4.3 Oncology / Cancer

4.3.1 Breast

4.3.2 Colorectal

4.3.3 Prostate

4.3.4 Others

4.4 Genetic Testing

4.5 HLA (Tissue Typing)

4.6 Microbiology

4.7 Cardiovascular Diseases

4.8 Neurological Diseases

4.9 Pharmacogenomics

4.10 Others

5. Technology - Molecular Diagnostics Market

5.1 PCR

5.2 Transcription-Mediated Amplification (TMA)

5.3 Hybridiazation (In-situ Hybridiazation & FISH)

5.4 DNA Sequencing & NGS

5.5 Microarray

5.6 Others

6. Region - Molecular Diagnostics Market

6.1 United States

6.2 Europe

6.3 India

6.4 China

6.5 Japan

6.6 Brazil

6.7 South Korea

6.8 Mexico

6.9 Russia

6.10 Rest of World (ROW)

7. End Users - Molecular Diagnostics Market

7.1 Hospitals & Academic Laboratories

7.2 Clinics and Commercial Laboratories

7.3 Others

8. Roche Diagnostics - Company Analysis

8.1 Merger & Acquisitions

8.2 Sales Analysis

9. Abbott Laboratories - Company Analysis

9.1 Merger & Acquisitions

9.2 Sales Analysis

10. Myriad Genetics - Company Analysis

10.1 Merger & Acquisitions

10.2 Sales Analysis

11. Qiagen - Company Analysis

11.1 Merger & Acquisitions

11.2 Sales Analysis

12. BioMrieux's Inc - Company Analysis

12.1 Merger & Acquisitions

12.2 Sales Analysis

13. Market Drivers

13.1 Various Developments in the Molecular Diagnostics Landscape

13.2 Integral to Traditional Labs

13.3 Improved Assay / Test Efficiencies

13.4 Targeting Antibiotic Resistance

13.5 Next Generation Ultrasensitive Molecular Diagnostics

13.6 Increasing Investment in Genomics & Proteomics Research

13.7 Technological Advances in Molecular Diagnostics

13.8 Increasing Acceptance of the Personalized Medicine

13.9 Growing Molecular Diagnostics for Food Safety

14. Challenges

14.1 Dearth of Trained Professionals

14.2 Regulatory Issues

14.3 Various Factors Slowing Growth of Molecular Diagnostics

14.4 Reimbursement Capabilities

14.5 Quality Checkpoints, Awareness & Acceptance

For more information about this report visit https://www.researchandmarkets.com/r/j3on5s

View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005474/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:
Global Molecular Diagnostics Market is Likely to Surpass US$ 22.5 Billion by the End of Year 2025 - ResearchAndMarkets.com - Yahoo Finance

Protein Detection and Quantitation Market Forecast 2020-2025, Latest Trends and – News by aeresearch

Posted on by

Latest Market Research Report onProtein Detection and Quantitation Market size | Industry Segment by Applications (Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology and Breeding and Animal Livestock), by Type (Bradford, Coomassie and BCA), Regional Outlook, Market Demand, Latest Trends, Protein Detection and Quantitation Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report on Protein Detection and Quantitation market strive to provide business professionals with an updated information on Protein Detection and Quantitation market, high growth markets, emerging business environments and latest business-centric applications. The Protein Detection and Quantitation market Analysis report provides a detailed analysis of sales channel and regional analysis of the Protein Detection and Quantitation market.

Likewise, Protein Detection and Quantitation Market report also assesses the key opportunities in the Protein Detection and Quantitation market and outlines the factors that are and will be driving the growth of the Protein Detection and Quantitation market share in current industry. The Protein Detection and Quantitation report is analyzed and forecasted for the previous and next five years of industry.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/85491

The key Protein Detection and Quantitation market players are weighed on a variety of factors such as company overview, product portfolios and recent development of the global Protein Detection and Quantitation market.

Top key playersof industry are covered in Protein Detection and Quantitation Market Research Report:

Split by product type,with production, revenue, price, market share and growth rate of each type, can be divided into:

Split by application,this report focuses on consumption, market share and growth rate of Protein Detection and Quantitation market in each application and can be divided into:

The predictions highlighted in the Protein Detection and Quantitation market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Protein Detection and Quantitation market. Across the past few years, the Protein Detection and Quantitation have seen the rise of influential market leaders in the space. The competition in the global Protein Detection and Quantitation market is dominated by the big players: Thermo Fisher Scientific, Promega, Genecopoeia, Labome and Garland Science

The Protein Detection and Quantitation market has shown growing trends over the years and anticipations are made that the Protein Detection and Quantitation market size would grow at a speedy pace in the upcoming years. Growth in the Protein Detection and Quantitation market would be primarily driven by application areas such as Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology and Breeding and Animal Livestock and product types segment like Bradford, Coomassie and BCA.

Outline of Protein Detection and Quantitation Market report covers:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/85491

See the rest here:
Protein Detection and Quantitation Market Forecast 2020-2025, Latest Trends and - News by aeresearch

The Gene Business – Business Today

Posted on by

Are you genetically predisposed to some diseases? Do you carry genetic mutations that can impact the health of your child? A debit card-sized IndiGenome card, recently unveiled by the government, will help you find the answers if your genetic information is captured in a database that India's umbrella research organisation - the Council of Scientific and Industrial Research (CSIR) - is building. Once your genome is sequenced from your blood sample and added to this database, the card can be used to read the information embedded in your genes, just as your debit card is used to generate a financial transaction statement from your bank's database.

Well, the card is not the key. Genome sequencing - or mapping the pattern of the basic building block of every living cell - is. A genome contains all of a living being's genetic material (simply put, the genome is divided into chromosomes, chromosomes contain genes, and genes are made of DNA). Each genome has approximately 3.2 billion DNA base pairs, and the way they are arranged, or variations and mutations in their pattern, can provide clues about the individual's health or ill health, inherited or acquired. Already, 1,008 individuals, chosen to represent India's social, ethnic and geographic diversity, have been issued such cards. Over 280 doctors in 70 institutions have been trained to make sense of such data. A CSIR institute, the Institute of Genomics and Integrative Biology (IGIB) - which is spearheading the Genomics for Public Health in India, also called IndiGen project - is planning to enrol 20,000 Indians for whole genome sequencing in the next couple of years to build a larger database. The data will be important for building the knowhow, baseline data and indigenous capacity in the emerging

area of precision medicine. IndiGen will have applications in a number of areas, including faster and more efficient diagnosis of rare diseases. The other benefits are cost-effective genetic tests, carrier screening applications for expectant couples, enabling efficient diagnosis of heritable cancers and pharmacogenetic tests to prevent adverse drug reactions.

In fact, IGIB leads two other programmes - Genomics for Understanding Rare Diseases India Alliance (GUaRDIAN) Network and Genomics and other Omics tools for Enabling Medical Decision (GOMED), led by Dr Mohammed Faruq, to see that the genome database and genetic screening leads to development of cost effective diagnostic tools and tests that are licensed out to private and public medical institutions.

The world over, fall in cost for genome sequencing (a reason for which is increase in computing power) is leading to path-breaking applications spanning the entire spectrum of healthcare - diagnosis to treatment and drug development to prevention and wellness - and unrelated fields such as agriculture, animal productivity, environment, sports and many more. Consider this: CSIR took six months to sequence the genomes of 1,008 Indians. Seventeen years ago, a global initiative led by the US National Academy of Sciences, had taken 12 years, and spent $3 billion, to complete the sequencing of the first human genome. Today, sequencing a person's genome does not cost more than $1,000. In fact, Sam Santosh, Chairman of MedGenome Labs, a private venture, says he can sequence a complete human genome in his Bengaluru lab for $500-600.

The Industry

The catalyst for the IndiGen project was advent of Next Generation Sequencing (NGS) in the last decade or so. (NGS helps an entire human genome to be sequenced in a day. The previous Sanger sequencing technology used to take over a decade.) The technology is being used by both IGIB and MedGenome for high-throughput sequencing, i.e. sequencing hundreds of thousands of genes in one go.

IndiGen is a good start but there are countries that are much ahead. Genomics England, a public-private partnership between the UK government and world's biggest NGS sequencing machine maker, Illumina, has completed sequencing of 1,00,000 genomes of British citizens comprising a mix of cancer patients, rare disorder patients and healthy people. A new agreement for sequencing of 3,00,000 genomes, with an option to increase it to 5,00,000 over the next five years, was signed by the two partners on January 13. "Countries such as Estonia and Iceland are attempting to sequence every single citizen and link the data with their health schemes. The US has decided to do it for every single rare disorder patient," says Praveen Gupta, Managing Director & Founder, Premas Life Sciences - the authorised partner of US-based Illumina in India.

"The global high-throughput genomics industry will be in the range of $10-12 billion. With an estimated 25-30 per cent annual growth, it is expected to become a $25-30 billion market in the next three-four years," he says. Premas sells tools (reagents, platforms, software, training) to labs that do genetic testing in India. With 90 per cent market share, it drives NGS technology in India, too. "The high-throughput genomics market in India, including reagents, instruments and services, will be about Rs 500 crore. Approximately 50,000 samples must be reaching India's clinical (service) market on an annual basis," says Gupta.

Dr Sridhar Sivasubbu and Dr Vinod Scaria, IGIB scientists at the forefront of the IndiGen programme, say genome sequencing is just one piece of the initiative. IGIB has two other programmes - Genomics for Understanding Rare Diseases India Alliance (GUaRDIAN) Network and Genomics and Other Omics Tools for Enabling Medical Decision (GOMED) - to ensure their genome database and genetic screening lead to development of cost-effective diagnostic tools and tests that can be licensed out to private and public healthcare institutions. "GUaRDIAN focuses on rare diseases. Given that we are a billion-plus people, even the rarest of the rare diseases is found in a few lakh people. So, this programme caters to 70 million people living with some genetic disease. We find technological solutions for these 7,000-odd diseases and partner with a network of 280 clinicians across 70-odd institutions to offer our solutions," says Sivasubbu.

"Patients and their families connect with us through the GUaRDIAN network. We sequence their genes to find the mutation, and once we find it, we go back to their communities with a cost-effective test to identify that mutation. You just have to look for that single mutation in others, and that's cost-effective," says Scaria. Instead of whole genome sequencing, which costs between Rs 50,000 and Rs 1,00,000, a single assay developed by IGIB through these programmes costs Rs 2,000. The team led by Sivasubbu and Scaria has developed 180 tests for 180 genes and transferred the technology to private diagnostic labs. The institute itself has catered to about 10,000 patients and carried about 25,000 tests in the last two years. "We have entered into partnerships with about a dozen companies. The format of the collaboration depends on the business models they follow," says Sivasubbu.

Premas Life Sciences

The authorised partner of US-based Illumina in India provides tools (reagents, platforms, software, training and troubleshooting) to labs engaged in genetic testing in India. With 90 per cent market share, it drives the New Generation Sequencing technology in India

It works in areas other than healthcare, too. For example, Tagtaste, an online platform for food professionals, uses the company's services to understand the genomics of taste. It has customers and partners such as Pepsico, Coca Cola, Nestle and ITC

Dr Lal PathLabs

The company has licensed diagnostic tests for 27 conditions from Institute of Genomics and Integrative Biology (IGIB)

Has a portfolio of more than 200 different types of tests

It is active in fields like rep- roductive health, cancer di- agnosis, pharmacogenomics

Medgenome Labs

The Bengaluru-based player considers itself as the private sector avatar of IGIB. It offers not just genetic tests but also carries out research. It has collaborated with Singapore's Nanyang Technological University to sequence 1,00,000 whole genomes from Asia. The Genome Asia project has already completed sequencing 10,000 whole genomes, of which about 8,000 are from India

MedGenomes research associates recently sequenced and analysed the genome of the Cobra snake. The findings, published in Nature, suggest the possibility of developing a new method of producing anti-venom completely in the lab.

Lifecell International

The company is in the genetic testing space. It has tied up with IGIB and offers tests ranging from basic screening (prenatal screening, newborn screening, etc) to high-end ones based on NGS. It tests more than 50,000 patient samples every month

Mahajan Imaging

The company has set up a new R&D wing to focus on cutting-edge scientific and clinical research and help radiology and genomics companies develop world-class clinically relevant products. The idea is to integrate imaging and genomic data

Trivitron Healthcare

The Chennai-based chain wants to develop tools using genomic data that can work on conventional platforms. It is talking to IGIB and trying to get its knowhow for manufacture of products for sale to pathology labs

The Private Hand

Dr Lal PathLabs, a pathology lab chain with big plans in the genetic testing space, has an entire department for such tests. "We offer tests of all levels - Karyotyping, which looks at the macro level, Microarrays, which offer intermediate resolution, and NGS, used to elucidate the DNA sequence at the micro level. The fields we are active in include prenatal reproductive health, cancer diagnosis and pharmacogenomics (study of how genes affect a person's response to drugs). We have more than 200 tests and conduct around 300 tests per day," says Dr Vandana Lal, Executive Director, Dr Lal PathLabs. The company has licensed tests for 27 conditions from IGIB. "The imported technology is expensive. The idea to partner with CSIR labs is to bring these cutting-edge technologies to Indian masses at a reasonable cost," says Dr Lal.

Lifecell International is another player in the genetic testing space that has tied up IGIB. "We offer tests ranging from basic screening (prenatal screening, newborn screening, etc.) to high-end ones based on NGS. We test more than 50,000 samples a month. PCR-based tests range from Rs 2,000-5,000 whereas tests based on NGS and those involving sequencing of large parts of the genome can cost upwards of Rs 20,000," says Ishaan Khanna, CEO, Biobank & Diagnostics, Lifecell. He believes the IndiGen database will help in development of better analysis and interpretation tools. "Our focus is on developing rapid genome testing for children in NICU (Neonatal ICU) and similar other scenarios where doctors need clear actionable results in the shortest possible time. IndiGen provides the right mix of Indian genome database," he says.

But not every partnership is for access to cost-effective tests. Mahajan Imaging, a medical imaging chain, has set up a Centre for Advanced Research in Imaging, Neuroscience and Genomics to focus on research and helping radiology and genomics companies develop clinically relevant products. The idea is to integrate imaging and genomic data. "We started the project six months ago and are among the first imaging companies to get into genomics. In the next three-five years, it will be possible for an AI algorithm to look at the radiology image and give genomic readings on it," says Vidur Mahajan, Associate Director, Mahajan Imaging.

Chennai-based Trivitron Healthcare sees in IndiGene data an opportunity to develop multiple testing platforms. It wants to develop tools using genomic data that can work on conventional platforms. "There are almost 1,00,000 pathology labs in India. Hardly 500-1,000 must be doing genetic testing. Companies like ours are talking to IGIB and trying to get the knowhow to manufacture products for a larger population," says Jameel Ahmad Khan, Head, R&D, Trivitron. "IGIB will develop the knowhow, provide proof of concept, and we will convert it into a product which pathology labs without highly trained manpower can also run," he says.

Bengaluru-based Medgenome Labs considers itself a private sector avatar of IGIB, perhaps even a couple of years ahead in research and development. The company not only does genetic tests but also carries out research. It has collaborated with Singapore's Nanyang Technological University to sequence 1,00,000 whole genomes from Asia. The Genome Asia project has already completed sequencing of 10,000 whole genomes, of which about 8,000 are from India. On December 4, international journal Nature published the initial findings from the project - genetic variation, population structure, disease associations, etc., from a whole-genome sequencing reference dataset of 1,739 individuals of 219 population groups and 64 countries across Asia. "We sequence a person's genes and other relevant parts of the genome for specific mutations to understand what is causing the disease and specific drugs and dosage the person will respond to. We also help pharmaceutical companies understand genomes and discover new drug targets and biomarkers," says Sam Santosh, Chairman, MedGenome. With about 120 sales people, the company claims it is generating samples from around 10,000 clinicians across the country. "We were the first to enter the market. In that sense, we created the market, and would be having 60-65 per cent market share. The sequencing market must be in the range of $70-75 million," says Santosh. The company expects its diagnostic business to touch $100 million in four years. Interestingly, MedGenome's research associates recently sequenced and analysed the genome of Cobra snake. The findings, published in Nature, suggest the possibility of developing a new method of producing anti-venom completely in the lab.

Other Sectors

Illumina's India partner Premas Life Sciences is not selling its next generation sequencers only to healthcare firms. Gupta says it has more than 200 installations in India alone. "Anything which is living has a DNA nucleic acid and can be sequenced. We have a mass research market and practically every institute has the sequencer. Somebody will be working on cow, somebody on rice, a third institute on some bacteria," says Gupta.

IGIB researchers Dr Sridhar Sivasubbu and Dr Vinod Scaria vouch for this. The institute is getting requests, including partnership offers, from non-medical players. Tagtaste, an online platform for food professionals, wants to understand the genomics of taste. "In a lighter vein, you could say that the efficiency of a professional wine taster depends on his genes," says Scaria. With customers and partners such as Pepsico, Coca Cola, Nestle and ITC, and a clientele that includes chefs of global hotel chains, taste is serious business. "The point is, if a person is paying Rs 3,000 for a curry or Rs 5,000 for a soup, you better get the taste right," says Scaria. IGIB also works with Adam's Genetics for R&D and product development in the area of fitness. "One of the companies works in the cricket industry. Each player can be genetically tested for performance and food intake because not all muscles have the same size and some people gain weight, some don't gain muscle mass, while some may be more prone to injury. Genetic tests can find out who is prone to injury, or whether weightlifting is the right exercise for a player or not," says Sivasubbu.

The Future

Indians are 17 per cent of the world's population. But only 0.2 per cent genomic data is from the Indian population. This is one area where India can lead. We have so many diseases, and if we can provide the genetic design, the world can develop diagnostics and therapies. "We can create ideas. We didn't invent computers but we created the IT industry. In the same way, we didn't invent genomic sequences but tomorrow we can create a genome informatics economy," says Premas' Gupta.

There are other possibilities, too. "A lot of pundits say that in the next five-six years, 15 per cent of the world's population will be whole genome sequenced. If I require 100 GB data for a genome sequence, for 1.5 billion people, 25-30 exabytes of data will be needed. The entire data content on YouTube, globally, is 0.8 exabytes. Imagine the kind of data generation and analytics possibilities we are talking about," says Gupta. "We need people to analyse this data. If we can take the lead and train our manpower, we can move the world, we can create a new industry which can lead for the next 20 years just the way the IT industry did," he adds. Incidentally, Gupta claims that TCS has already bought Illumina's sequencing platform. So has WIPRO. It seems IT companies are already sensing an opportunity.

Sivasubbu says it took India 10 years to scale up from sequencing one genome to 1,000 genomes. "In the next decade, it may be a million."

@joecmathew

Continue reading here:
The Gene Business - Business Today

YOUR HEALTH: What can be done when the medicines you need make you even sicker? – WQAD Moline

Posted on by

Please enable Javascript to watch this video

PALO ALTO, California One medical center has developed an innovative program that uses new technology, genetics, and other tools to personalize care.

For Debbie Spaizman, it means actually getting the help she needs.

She needed surgery, but she hesitated due to how she reacted to pain medication.

"My head would spin. I really was foggy, and I had itching all over my body," she explained.

"I had no pain relief at all. I thought twice about having the surgery."

To get answers, Debbie enrolled in the HumanWide Project at Stanford Medical School.

The study flips the model on healthcare by personalizing treatment.

That includes a deep dive into pharmacogenics.

"Pharmacogenomics specifically tests for genes that look at the rate in which we metabolize drugs," said Dr. Megan Mahoney, Clinical Professor of Medicine at Stanford University.

"It can determine the dosing of medications and also predict any side effects."

That means our genes can play a big role in how we respond to medicine.

And so, with a quick swab of the cheek, Debbie finally got answers.

"The result of the test showed that I'm a slow metabolizer. Drugs will stay in my system longer than they will for someone else."

With that, a plan started to come together for Debbie.

"We were able to identify the class of opioids that would work for her based on her pharmacogenomic make-up and then she was able to go through with the surgery," said Dr. Mahoney.

Debbie is grateful.

"It was life changing for me."

And she's not the only one.

"25% of patients had a change in their dose of medication based on the pharmacogenomics test," said Dr. Mahoney.

It's an approach that Debbie calls an "absolutely game changer."

Stanford is not the only one paying attention to pharmacogenics.

The US Department of Veteran Affairs is making a big push to personalize medicine for its vets.

The program will enroll those with a history of cancer, but will also inform doctors how patients will metabolize other medicines they need.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at jim.mertens@wqad.com or Marjorie Bekaert Thomas at mthomas@ivanhoe.com.

More:
YOUR HEALTH: What can be done when the medicines you need make you even sicker? - WQAD Moline

Drug Discovery Technologies Market Research, Recent Trends and Growth Forecast 2 – News by aeresearch

Posted on by

Latest Market Research Report onDrug Discovery Technologies Market size | Industry Segment by Applications (Biopharmaceutical companies, Pharmaceutical companies, Research institutes and Biotech companies), by Type (Biochips, High throughput screening, Pharmacogenomics, Genomics, Bioanalytical instruments, Bioinformatics, Nanotechnology and Others), Regional Outlook, Market Demand, Latest Trends, Drug Discovery Technologies Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The research report on Drug Discovery Technologies market has integrated the analysis of different factors that boost the Drug Discovery Technologies markets growth. It establishes trends, restraints and drivers that transform the Drug Discovery Technologies market in either a positive or negative manner. The detailed information is based on current Drug Discovery Technologies market trends and historic achievements.

This section of the report identifies various key manufacturers of the Drug Discovery Technologies market. It helps the reader understand the strategies and associations that players are focusing on combat competition in the Drug Discovery Technologies market. The Analysis report on Drug Discovery Technologies Market provides a significant in-depth analysis of the market.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/55919

Top key playersof industry are covered in Drug Discovery Technologies Market Research Report:

Split by product type,with production, revenue, price, market share and growth rate of each type, can be divided into:

Split by application,this report focuses on consumption, market share and growth rate of Drug Discovery Technologies market in each application and can be divided into:

The foremost points are labelled in detail which are covered in this Drug Discovery Technologies Market Report:

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Drug Discovery Technologies market. It also provides an overview and forecast for the Drug Discovery Technologies market based on all the segmentation provided for the global region.The predictions highlighted in the Drug Discovery Technologies market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Drug Discovery Technologies market.

The Drug Discovery Technologies market has shown growing trends over the years and anticipations are made that the Drug Discovery Technologies market size would grow at a speedy pace in the upcoming years. Growth in the Drug Discovery Technologies market would be primarily driven by application areas such as Biopharmaceutical companies, Pharmaceutical companies, Research institutes and Biotech companies and product types segment like Biochips, High throughput screening, Pharmacogenomics, Genomics, Bioanalytical instruments, Bioinformatics, Nanotechnology and Others.

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/55919

See the article here:
Drug Discovery Technologies Market Research, Recent Trends and Growth Forecast 2 - News by aeresearch

Pharmacogenomics Market: Leading Segments and their Growth Drivers – TheInfobiz

Posted on by

A leading research firm, Zion Market Research added a latest industry report on "Global Pharmacogenomics Market" consisting of 110+ pages during the forecast period and Pharmacogenomics Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Pharmacogenomics Market.

According to the report the Pharmacogenomics Market: Leading Segments and their Growth Drivers

The Pharmacogenomics Market report provides in-depth analysis and insights into developments impacting businesses and enterprises on global and regional level. The report covers the global Pharmacogenomics Market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global consumer electronics market.This report studies the global Pharmacogenomics Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Pharmacogenomics Market by companies, region, type and end-use industry.

Request a Free Sample Report on Pharmacogenomics Market:https://www.zionmarketresearch.com/sample/pharmacogenomics-market

The Pharmacogenomics Market report mainly includes the major company profiles with their annual sales & revenue, business strategies, company major products, profits, industry growth parameters, industry contribution on global and regional level.This report covers the global Pharmacogenomics Market performance in terms of value and volume contribution. This section also includes major company analysis of key trends, drivers, restraints, challenges, and opportunities, which are influencing the global Pharmacogenomics Market. Impact analysis of key growth drivers and restraints, based on the weighted average model, is included in this report to better equip clients with crystal clear decision-making insights.

The Pharmacogenomics Market research report mainly segmented into types, applications and regions.The market overview section highlights the Pharmacogenomics Market definition, taxonomy, and an overview of the parent market across the globe and region wise.To provide better understanding of the global Pharmacogenomics Market, the report includes in-depth analysis of drivers, restraints, and trends in all major regions namely, Asia Pacific, North America, Europe, Latin America and the Middle East & Africa, which influence the current market scenario and future status of the global Pharmacogenomics Market over the forecast period.

Get Free PDF Brochure of this Report: https://www.zionmarketresearch.com/requestbrochure/pharmacogenomics-market

The Pharmacogenomics Market report provides company market size, share analysis in order to give a broader overview of the key players in the market. Additionally, the report also includes key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product and regional expansion of major participants involved in the market on the global and regional basis.

Major Company Profiles Covered in This Report:

Dynamic DNA Laboratories, Abbott Laboratories, Empire Genomics, LLC, Illumina, Inc., F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., OneOme LLC, Thermo Fisher Scientific, Inc., and OPKO Health, Inc. among others.

Some of the major objectives of this report:

1) To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Pharmacogenomics Market.

2. To provide insights about factors affecting the market growth. To analyze the Pharmacogenomics Market based on various factors- price analysis, supply chain analysis, porter five force analysis etc.

3. To provide historical and forecast revenue of the Pharmacogenomics Market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World.

4. Country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Pharmacogenomics Market.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

See the article here:
Pharmacogenomics Market: Leading Segments and their Growth Drivers - TheInfobiz

Manchester to add master’s degree in nutrition with DNA twist – FW Business

Posted on by

In the future, nutritionists and dietitians will have a new tool for studying the relationship between a persons nutrition and health theyll be adding DNA into the mix.

Manchester University is moving ahead with plans to offer a master of science degree in nutrition and nutrigenomics (MSNGx).

It builds on Manchesters masters degree in pharmacogenomics, which is the study of DNA and medication. Manchester is the first university in the nation to offer that degree.

To our knowledge, the MSNGx program would be the first of its kind in the country, said Teresa Beam, Pharmaceutical Sciences Department chair and professor of pharmaceutical sciences and pharmacogenomics at Manchesters Fort Wayne campus.

Manchester University will train the nutritionist of the future, she said. The program will be divided into two phases: three years of undergraduate study at the North Manchester campus and two years of professional study at the Fort Wayne campus.

Jeff Beer will be responsible for the first three years the undergraduate phase. Beam will lead the graduate-level phase in Fort Wayne.

In lay terms, the program will teach nutritionists how to use an individuals DNA to make better nutrition choices. Beam said eventually, with additional research the body of evidence will grow and nutritionists and dietitians will be better able to match diets to genes, the gut microbiome and metabolism.

The ultimate goal of this new field, Beam said, is to use nutrigenomics to improve health and make healthier communities. Complex diseases such as cancer, diabetes and heart disease could some day be better managed when an NGx-trained nutritionist is part of patients health care teams.

The importance of diet in preventing and treating complex diseases is well-known, she said. Food as medicine is emerging as a necessary component of managing complex diseases.

In Spring 2020 the university plans to hire an MSNGx program director. By the end of 2020 the MSNGx application should be submitted to the accrediting council. The accreditation site visit will be in spring of 2022 and the first students will be admitted in fall 2022.

Nutrigenomics also has the potential to improve athletic performance. Genetics can influence the bodys ability to recover from injury, generate inflammation or cause oxidative stress, Beam said. Genetics can also affect performance. All are factors that can be considered when constructing athletic training regimens, designing physical therapy treatments or optimizing game strategies.

Read more from the original source:
Manchester to add master's degree in nutrition with DNA twist - FW Business

Global Pharmacogenomics (PGx) Market Research Report 2020 Overall Analysis and Forecast up to 2025 – Fusion Science Academy

Posted on by

Global Vascular Patches Market Report Market Size, Share, Price, Trends and Forecast is a professional and in-depth study on the current state of the global Vascular Patches industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. The compilation also covers information about clients from different industries, which is very important for the manufacturers.

There are 4 key segments covered in this Vascular Patches market report: competitor segment, product type segment, end use/application segment, and geography segment.

Request Sample Report @ https://www.marketresearchreports.biz/sample/sample/6900?source=atm

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India Companies

The information for each competitor includes:

* Company Profile

* Main Business Information

* SWOT Analysis

* Sales, Revenue, Price, and Gross Margin

* Market Share

Send Enquiry On This Report @ https://www.marketresearchreports.biz/sample/enquiry/264?source=atm

key players operating in the market during the forecast period, primarily due to the rise in patient pool for the condition. Biologic vascular patches offer several benefits over synthetic vascular patches, in terms of reduced rates of infection, biocompatibility, and ease of use. Based on end-user, the global vascular patches market can be segregated into specialty clinics, hospitals, ambulatory surgical centers, and others

Based on geography, the global vascular patches market can be segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Furthermore, the North America vascular patches market can be split into U.S., and Canada. The vascular patches market in Europe can be further bifurcated into U.K., Germany, France, Italy, Spain, and Rest of Europe. The Asia Pacific vascular patches market is further sub-segmented into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific. The vascular patches market in Latin America can be further split into Mexico, Brazil, and Rest of Latin America. The Middle East & Africa Vascular Patches market can be sub-segmented into Saudi Arabia, Israel, South Africa, and Rest of Middle East & Africa. North America dominated the global vascular patches due to factors such as Increase in incidence of target diseases, rise in per capita health care expenditure, shift in focus of governments toward providing better health care facilities, advanced technological innovations, and rise in medical tourism. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to factors such as increasing awareness regarding advanced vascular products and the presence of a large patient population.

Major players operating in the global vascular patches market include Labcor Laboratrios Ltda, LeMaitre Vascular, Inc., Terumo Corporation, Becton, Dickinson and Company, B. Braun Melsungen AG, MAQUET Holding B.V. & Co. KG, W. L. Gore & Associates, Inc., Admedus, CryoLife, Inc., Baxter, and Edwards Lifesciences Corporation.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

The main aim of the report is to:

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

Important key questions answered in Vascular Patches market report:

What will the market growth rate, overview, and analysis by type of global Vascular Patches in 2029?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Vascular Patches market?

What is dynamics, this overview includes analysis of scope and price analysis of top manufacturers profiles?

What are the opportunities, risks, and the driving forces behind of Vascular Patches market? What are the major upstream raw materials sourcing and downstream buyers?

What is the business overview by type, applications, gross margin, and market shares?

What are the opportunities and threats faced by manufacturers in the global Vascular Patches market?

Check Discount On This Report @ https://www.marketresearchreports.biz/sample/checkdiscount/6900?source=atm

We are a vibrant market research company which is focused on catering to more and more people day by day. Our research company is one of a few reliable market research report companies in todays date.

Visit link:
Global Pharmacogenomics (PGx) Market Research Report 2020 Overall Analysis and Forecast up to 2025 - Fusion Science Academy

Analysis on the World’s Bioinformatics Market 2017-2019 and Forecast to 2023 – Review of Challenges & Opportunities following the Adoption of…

Posted on by

DUBLIN, Nov. 21, 2019 /PRNewswire/ -- The "Bioinformatics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The scope of the study encompasses the global bioinformatics market based on geography, category, and application. It provides a detailed analysis of recent advances in omic technologies and examines their impact on the bioinformatics market.

It discusses the ways in which bioinformatics has been utilized by the pharma and biotech industries to streamline the research and development (R&D) process and improve efficiencies. It provides a detailed analysis of the leading countries, companies, and technologies that will drive the field forward.

The report includes:

The rapid growth in raw data generation and advances in IT software and infrastructure have enabled researchers to integrate disparate datasets in order to decipher complex biological processes and develop predictive models of disease, for the purposes of identifying and validating novel biomarkers and developing precision medicines.

Since scientists unraveled the blueprint of the human genome more than 10 years ago, they have been exploring new ways to utilize omic data to understand more complex diseases. Researchers are eager to analyze as many different types of data as possible to gain a better understanding of what is happening at the cellular and molecular levels. Service providers have developed new analytical tools and IT infrastructures to enable scientists to interrogate complex data sources and quickly and efficiently disseminate information for better decision-making to achieve this goal.

More recently, improvements in cloud computing capabilities, advances in data analysis software services and the growth of NGS technologies have helped to expand the evaluation of available datasets, allowing researchers to build systems biology models of various diseases.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Global Bioinformatics Market: Overview

Chapter 4 Bioinformatics: Data Generation and Data Management

Chapter 5 Bioinformatics: Data Analysis and Software

Chapter 6 Bioinformatics: Data Processing and Storage

Chapter 7 Bioinformatics: Sequencing Services and Platforms

Chapter 8 Bioinformatics: Sequencing Applications

Chapter 9 Bioinformatics Applications in Pharmaceutical R&D

Chapter 10 Market Trends and Analysis

Chapter 11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/ywqdiu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the article here:
Analysis on the World's Bioinformatics Market 2017-2019 and Forecast to 2023 - Review of Challenges & Opportunities following the Adoption of...

Jipmer conducts JIPP 2019 – United News of India

Posted on by

More News26 Nov 2019 | 2:49 PM

Thiruvananthapuram, Nov 26 (UNI) National Institute of Speech and Hearing (NISH) has celebrated the 70th Constitution Day at its campus in Akkulam on Tuesday.

Sabarimala, Nov 26 (UNI) As many as 8 Ayyappa devotees were injured, two of them seriously, when a huge tree fell on them while they were trekking on the Chandranandan road near Marakkuttam, here in the wee hours on Tuesday.

Mangaluru, Nov 26 (UNI) ACP Squad in an operation arrested an Indian Army imposter Manjunath Reddy who was posing himself as Indian Army Junior Commissioned officer, at a his residence in Suratkal.

Mysuru, Nov 26 (UNI) Karnataka Chief Minister BS Yediyurappa on Tuesday expressed confident that BJP would sweep the upcoming 15 Assembly seats and that would put an end to all talks around mid-term polls in the state.

Udupi, Nov 26 (UNI) District Administration and police have warned devotees and tourists about fake website created by miscreants in the name of Sri Mookambika Temple at Kollur.

Originally posted here:
Jipmer conducts JIPP 2019 - United News of India

Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT – Yahoo Finance

Posted on by

Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq:IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Companys ThyGeNEXT test, representing an increase of approximately $2,400 per assay over previous reimbursement coverage. This increase in reimbursement rates reflects the expansion of the ThyGeNEXT panel to aid in identifying the appropriate patients for surgery. In 2018, Interpace processed approximately 12,500 ThyGeNEXT tests.

Prior to the new LCD code (81455) becoming effective, it was subject to a public comment period, which ended December 15, 2019, and is now subject to an analysis and review period by MACs Medical Directors. Final approval is expected during the first quarter of 2020. ThyGeNEXT has been covered by an existing LCD since it was launched in mid-2018 and its predecessor, ThyGenX, has been covered since 2014.

Jack Stover, President & CEO of Interpace, said, I am very pleased with the draft local coverage announcement and look forward to the final determination, which when approved will demonstrate the quality of our expanded assay, and most importantly supports continued reimbursement for patients and their families potentially affected by Thyroid cancer.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and Commercial insurers, with more than 280 million members covered.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpace Biopharma provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Story continues

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

See more here:
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT - Yahoo Finance

IT will be key to precision medicine’s success in 2020 – MedCity News

Posted on by

Progress in genomic science has been astronomical over the past few years. In fact, the tipping point that validated the clinical significance of genetic/genomic testing is barely visible in the rearview mirror. As a result, stakeholders ranging from clinicians to regulatory agencies, to professional associations, to payers have begun championing the value that precision medicine delivers in terms of better diagnoses and more effective therapeutic interventions.

For example, in educational materials explaining incidence of dilated cardiomyopathy (DCM), the American Heart Association notes that a full third of DCM patients inherit the condition from their parents or other family members. Germline testing can identify patients with this genetic variant, leading clinicians to a faster diagnosis and earlier treatment. The Food and Drug Administration (FDA) has stated its commitment to approving targeted therapies based on genetic mutations as appropriate. Payers are beginning to issue reimbursement policies to cover the cost of genetic/genomic testing. United Healthcare, for instance, began covering pharmacogenomic panels for patients with anxiety and depression this October.

This leads us to the next great transformation necessitated by precision medicine: implementing the technology infrastructure to govern the ordering and resulting processes inherent to genomics, as well as finding ways to manage the great volumes of data generated by testing.

Precision medicine is already being pursued sporadically across many, if not most, healthcare organizations. Oncologists are likely to be ordering somatic tests to better profile patient tumors so targeted therapies can be delivered. Family practice, behavioral medicine and psychiatric departments are using pharmacogenomics to understand how well (or poorly) patients metabolize specific medications and which might trigger side effects or safety concerns. These insights allow them to prescribe the right treatment at the right dose the first time around instead of spending months on a trial-and-error approach.

Cardiovascular and neurology specialists (among others) order germline tests to help them diagnose, treat and gain new insights into many common conditions such as congestive heart failure, arrhythmias, aneurysms, epilepsy, nerve pain and dementia. Some health systems even order germline tests on all newborns so a full genetic profile is available which can be used throughout the individuals lifetime.

The value of the data being generated through these clinical pockets cannot be understated. It carries information that can be used across a multitude of care settings far into the future to help providers and specialists arrive at more accurate diagnoses faster, and identify the most effective treatment sooner. This, in turn, can help healthcare leaders move the needle to improve quality efforts and optimize revenue while reducing the risk associated with poor outcomes.

To realize full value, however, healthcare organizations must ensure genetic/genomic test results are readily available to clinicians at the point of care and in a vocabulary that makes them meaningful. Unfortunately, few health systems have invested in the IT resources that can make this possible. Currently, test results are ordered in a vacuum and results are often returned in a PDF that will be hard to access. In addition, the information is relayed in a nomenclature unfamiliar to clinicians, so they struggle to understand how to apply the results to specific patient circumstances.

Unless these concerns are addressed, healthcare will simply reenact a mistake made years ago with the advent of electronic health records: valuable data that can immediately and directly impact care will be locked in a silo, unavailable during clinical decision-making.

As the industry heads into 2020, it must make plans and take action to get ahead of this looming problem. Healthcare IT professionals must be brought to the table to help organizations strategize about their precision medicine initiatives. The key to success with this new standard of care is recognition that data generated by genetic/genomic tests can be used endlessly across the enterprise and over the long term as patient conditions change. Organizations must seek out platforms that will consume genomic test results as discrete data and integrate it with patient-specific clinical information. Likewise, the platforms must be made available within existing workflows, so clinicians can leverage it during decision making and can interrogate the data as patient conditions change and genomic science delivers new insights.

Picture: Feodora Chiosea, Getty Images

Read the original:
IT will be key to precision medicine's success in 2020 - MedCity News

Alphabet-Backed Insurer Clover Health Committing to Home-Based Strategy – Home Health Care News

Posted on by

Clover Health similar to many other Medicare Advantage (MA) players has its sights firmly set on the home.

But unlike its larger and older MA peers, the relatively smaller and newer Clover isnt held back by certain structural constraints. That ability to build a home-focused model from the ground up is a big part of Clovers future, Chief Scientific Officer Kumar Dharmarajan told Home Health Care News.

And the technology-enabled Clovers future is bright: Founded in 2013, San Francisco-based Clover has raised about $925 million since launching. Among its backers: Google parent company Alphabet Inc. (Nasdaq: GOOGL).

HHCN recently caught up with Clovers Dharmarajan to learn all about its in-home care ambitions, its approach to partnerships and evolution into a payer-provider hybrid.

Highlights from that conversation are below, edited for length and clarity.

Dharmarajan: If youre asking about specific bids and plan offerings, those vary by location. Clover doesnt just have one U.S. plan, in other words.

We have a number of different offerings where we engage with members in the home. One of those is our in-home care program, where we provide in-home primary care services for some of our most vulnerable members, people with multiple chronic conditions, frailty and advanced illness.

Many of these folks are frequently hospitalized and have limited life expectancies. For those members, we wanted to provide a technology-enabled house calls experience. House calls have been shown by CMS and some of its demos to be really important to those who have trouble accessing care, including those who are homebound.

Advertisement

Many of the Clover members in this program do have difficulty leaving the home.

We give them access to physicians, nurses, social workers people who will see them monthly if needed. Theyll spend an hour or so at a time with our members. Contrast that to getting 10 minutes with your doctor in the office.

We focus on very comprehensive, holistic care thats aligned with members values, preferences and prognosis. We provide a number of interventions that are on the cutting-edge side.

We do pharmacogenomics testings. We want to make sure members medication regimens are best-aligned with how their bodies metabolize drugs. A lot of folks are on 10, 15 medications.

In some of these cases, its like a witchs brew, right? We want to make sure the regimen our members are on promotes their health and doesnt cause side effects.

For some of our members, we also give them access to what we call the Clover button, which is an ability for them to contact their provider directly. They dont have to remember a phone number. They just press a button, then they could talk through that and speak with their medical team.

And we do a bunch of other things where we really integrate payer and provider. Clover is a technology-enabled health insurance company, but this in-home care practice, this house calls practice is wholly owned by Clover.

Clover the health plan has access to a lot of different streams of medical information that we provide to Clover the practice.

For example, we often know when a member of ours is hospitalized or heads to the ER. We can get real-time data feeds a lot of times from those institutions. We then feed that info to the medical practice so they know exactly when a person leaves. In turn, we can engage with those individuals in the home as soon as theyre discharged.

Were really excited about that partnership between plan and provider.

At this point, Clover does not provide skilled home health services and things that fall into that bucket. We do have social workers who see our members and help with financial challenges. We have nurses who are part of our team, experts who are well-trained in, for example, wound management.

Were not trying to be a home health agency, but we do have some of those skillsets naturally within the team. And we do partner with home health agencies to really advance the care of our members.

In general, home health is probably underutilized for a lot of frail elders. We look to use home health care wherever it could benefit a member.

Unfortunately, its not a coincidence that some of the sickest, most vulnerable patients are also the most vulnerable from a social perspective, whether thats in regard to finances, housing, food or language barriers. For us, addressing social determinants is just part and parcel of the practice.

Its not something that we see as a unique strategy or something new that we need to suddenly start doing.

Its certainly en vogue now to talk about addressing social determinants of health. We just think its always been very core to the model of, you know, improving care for homebound older adults.

Regardless of that, committing to a home-based strategy is something that Clover has been interested in doing and has been investing in for some time. Home-based care is very scalable compared to brick and mortar.

Its also clear to us that home-based care allows you to pick up on and address issues that you would never see in an office setting. You go into the home of an older adult, you see six different bottles of insulin, all of which are different. This literally just happened with one of our members, who was actually blind. She didnt know which [insulin] to take.

When you go into the home, you see that. You can see whats in the refrigerator. You can engage with family members. Theres an incredible amount of data.

With our in-home care program, weve seen reductions in [hospital] admission rates, reductions in ER visitation rates. Weve seen reduced medical expenses overall. And weve heard from a lot of members who are just positive and grateful for the program.

Many people have never had house calls before.

I dont think I can tell you our specific partners at this point. But generally, I think there are a few things that are very important to us.

One is responsiveness. If you have a home health need, being able to quickly make the referral and have a team get in there ASAP is so critical.

Also having bi-directional communication is important. Once the home health provider is in there working with our member, we want to hear from that provider if they see something theyre concerned with. Even if its just, The member doesnt look at good today.

Provider groups need to be collaborators and, in a sense, sensors. Home health providers might be in the home more frequently than we are, depending on a members needs.

We have spoken with some and have embarked on some pilots. We do recognize that non-skilled services are an important part of the overall picture.

Read more:
Alphabet-Backed Insurer Clover Health Committing to Home-Based Strategy - Home Health Care News

PGRN Hub – PGRN Hub

Posted on by

PGRN-Hub will encourage and support participation of all investigators with an interest in precision medicine through establishment of an efficient and innovative infrastructure that promotes scientific exchange through the following aims:

Aim 1.Provide support and infrastructure for PGRN meetings, conference calls and webinars that use information technologies and novel meeting activities to enhance communication and scientific exchange. In particular, we will provide logistical and technical support for (a) at least two PGRN annual meetings at designated PGRN sites and (b) regular conference calls and webinars.

Aim 2.Establish a PGRN Virtual Home to enhance and promote communications among PGRN members and with scientific and public audiences while attracting new membership. In particular, we will (a) develop and promote a web interface to unify, organize, and display all PGRN resources and activities at pgrn.org; (b) host lectures and display professional-quality presentations that highlight up-to-date PGRN accomplishments; and (c) establish an intranet to handle PGRN meeting logistics and to support PGRN webinars and internal collaborations.

Aim 3.Promote a collaborative and synergistic network by (a) incorporating networking opportunities into our meetings; (b) soliciting open proposals to develop and incubate new ideas for collaborations; and (c) providing access to information from key resources that will support the conduct of the proposed collaborative projects including PGRN Enabling Resources such as RPGEH.

Read the original post:
PGRN Hub - PGRN Hub